European Psychiatry - Volume 33 - March 2016

769 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S765
Aims – To analyze the proportion of patients treated with more
than one antipsychotic;
– to study clinical as sociodemographic variables associated with
types of prescription.
Methods Retrospective descriptive study of treatment prescribed
to psychiatric inpatients treated in an acute care unit of Psychiatry
Service in a large teaching hospital during a period of 3 years. Con-
secutively admitted inpatients receiving concurrent antipsychotics
were compared with those treated with a single antipsychotic. Pre-
scription drug records at discharging were revised, n = 263.
Results From the total sample, 61% received more than one
antipsychotic. The most common types of combinations were
atypical plus a typical antipsychotic followed by two atypi-
cal antipsychotics, being less frequent combination of three or
more antipsychotics. There were 19 different drug combinations.
Concurrent antipsychotics were most frequently prescribed in
schizophrenia and schizoaffective disorder. Patients with more
previous episodes of illness received more frequently concurrent
antipsychotics than patients with lownumber of previous episodes
of illness (P < 0.03). Patients with longer time of hospitalization, and
age between 30 and 50 years were treated more frequently with
several antipsychotics. Analysis with other variables is presented
in the study.
Conclusions There is a significant difference in the strategies of
treatment with antipsychotics depending on diagnosis and num-
ber of previous episodes of illness. The concurrent use of multiple
antipsychotics in psychiatric inpatients appears to be a response to
treatment resistance and is frequent in schizophrenic patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1305
Brief psychotherapy in eating
disorders
E. Garcia ∗ Leon olo Martinez
1 Ciudad Real, Spain
2 Hospital General de Ciudad Real, UTCA, Ciudad Real, Spain
3 Hospital General de Ciudad Real, USMIJ, Ciudad Real, Spain
∗ Corresponding author.
First time we began to work with eating disorders, we used to
hear the chronic course of the illness and the long-term treatment
that our patients would need. When you have a team trained in
brief psychotherapy, but not in this specific area, it sounds as just
the opposite you try to reach with your patients. National guide-
lines however are full of psycho-educational and cognitive-conduct
treatment’s models, without any other validated kind of treatment.
However, it was our experience that solution focused or prob-
lem focused therapy were also two clinical effective approaches
to many psychiatric problems. In fact, we had a mature consult,
in which as far as two thirds of patients had become, some way
chronic. Problem was, as far as we can imagine, if that was a dis-
ease’s effect or a lack of a deeper intervention, which were wider
than those classic. So, we classified our patients in resistant or not
resistant, and doing so we add brief therapy to the first group,
reevaluating every week each intervention and the course of the
illness. By doing so, we found that chronicity was, in same cases,
just the result of limited treatments. Here we have analysed some
chronic patientswith a bad course and the alternatives that let them
to recover.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1306
Tech Connect: An innovative pilot
intervention to improve treatment
adherence for adolescents with mood
disorders
R. Gearing ∗, K. Moore , R. Guetta
1 University of Houston, GCSW, Houston, USA
2 Columbia University, Columbia, New York, USA
3 North Shore Child and Family Guidance Center, Child and Family,
New York, USA
∗ Corresponding author.
Introduction Over a third of adolescents terminate prematurely
from mental health treatment. A core underlying assumption of
most, if not all, evidence-based psychosocial interventions is that
patients will fully and actively engage in the treatment protocol.
Poor adherence remains a fundamental challenge in the treatment
of mood disorders in adolescents. Tech Connect is a proactive,
technology-assisted intervention of manualized between session
contacts and structural supports to increase adherence of ado-
lescents with depression who are at high risk of dropout from
treatment.
Objective To test Tech Connect in a randomized controlled trial
(RCT) with depressed adolescents by:
– assessing feasibility;
– estimating preliminary intervention parameters;
– investigating adherence and mental health outcomes.
Methods An RCT with depressed youths (13–17 years) who
were at high-risk for premature dropout were randomized to
Tech Connect (treatment condition) or standard community-based
care (control condition). Standardized measures assessed mental
health symptoms and outcomes, health beliefs, family involve-
ment, adherence, and therapeutic alliance.
Results Results found significant differences between the num-
ber of treatment sessions attended by the adolescents assigned to
Tech Connect and those of the control group.
Conclusions Tech Connect was designed to increase sessional
adherence in the early phase of treatment. All adolescents in the
treatment condition attended the first treatment session, with 90%
attending the targeted first 8 sessions. In comparison, only 40% of
adolescents in the control condition completed the first 8 sessions.
The Tech Connect Program is a novel, technologically driven inter-
vention designed to address this gap by improving engagement and
adherence to treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1307
Antidepressants and thyroid
hormones
S. Gómez Sánchez ∗, L. Rodríguez Andrés ,
A. Rodríguez Campos , C. Noval Canga , A. Álvarez Astorga ,
A. San Román Uría , G. Isidro García , M. Hernández García ,
T. Ballesta Casanova , L. Gallardo Borge
1 Hospital Clínico Universitario de Valladolid, Psiquiatría, Valladolid,
Spain
2 Complejo Asistencial de Zamora, Psiquiatría, Zamora, Spain
∗ Corresponding author.
Introduction Over the years, it has been shown that various
psychopharmaceuticals cause alterations on thyroid function. The
objective of this review is to summarize the most important thy-
roid side effects associated with them. Special attention is paid to
antidepressants, which are widely used and whose side effects are
not receiving the attention they deserve.
Clinical cases This review presents three cases of patients who
were undergoing treatment with venlafaxine. Before the start of